Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to a loss of $1.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.63%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.59 per share when it actually produced a loss of $1.54, delivering a surprise of +3.14%.Over the last four quarters, the comp ...